Haines Stuart T, Fuke Dawn C, Lender Dan, Rodgers Philip T, Sysko Suzanne K
School of Pharmacy, Division of Endocrinology, Diabetes, and Nutrition, School of Medicine, University of Maryland, Baltimore, Maryland 21201-1082, USA.
Pharmacotherapy. 2006 May;26(5 Pt 2):32S-41S. doi: 10.1592/phco.26.5part2.32S.
Reducing the risk for coronary heart disease (CHD) requires a comprehensive assessment of cardiometabolic risk factors along with the initiation of nonpharmacologic and pharmacologic therapies to mitigate these risk factors. A case study is presented to illustrate the approach to evaluating a patient and selecting among available and emerging therapeutic modalities to reduce CHD risk.
降低冠心病（CHD）风险需要对心血管代谢危险因素进行全面评估，并启动非药物和药物治疗以减轻这些危险因素。本文通过一个案例研究来说明评估患者以及在现有和新出现的治疗方式中进行选择以降低冠心病风险的方法。
